NCT05897645Recruiting
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke
High-resolution Magnetic Resonance Imaging of Intracranial Atherosclerotic Plaques in Ischemic Stroke (HRMRI-ICAS): a Prospective, Multicenter Cohort Study
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
Intracranial atherosclerotic disease is the most common cause of ischemic stroke in Asia, also in China. Currently, despite vascular recanalization therapy, statins are one of the main drug choices for treating atherosclerotic plaque. High resolution magnetic resonance imaging (HRMRI) can accurately assess the status of intracranial and extracranial arterial plaque, and has high consistency with histopathology. Thus, HRMRI technology has been widely used to monitor the efficacy of drug treatment for atherosclerotic plaque in clinical trials or practice. As a non-invasive technique, HRMRI make it possible to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery in vivo. It can quantitative analysis including components such as lipid-rich necrotic core, fiber cap thickness, intra-plaque hemorrhage, calcification, etc. Therefore, it is crucial for evaluating the etiology of ischemic stroke and developing secondary prevention strategies. At present, there is a lack of large-scale and prospective study to evaluate the etiology of ischemic stroke including cryptogenic stroke based on HRMRI. In this context, this study aims to establish a multi center HRMRI database of intracranial arteries among Chinese patients with ischemic stroke.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2110 (estimated)
- First submitted
- 23 May 2023
- Start date
- Jan 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT05897645
What you commit to
- Study type: Observational
- Planned participants: 2110
- From Jan 2023 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Intracranial hemorrhage found by head CT
- 4\. Comorbidity with any serious diseases and life expectancy is less than one year
Other
- 2\. Had a contraindication to MRI,or could not complete required MRI sequences
- 3\. Intracranial tumor, arteriovenous malformation, or aneurysm
- 5\. Pregnancy
- 6\. Patients not suitable for this clinical studies considered by researcher
Who the study is looking for
- 1\. Patient age ≥40 years
- 2\. Time of stroke onset: within 2 week
- 3\. Baseline NIHSS score ≤16
- 4\. Ischemic stroke confirmed by head CT or MRI
- 5\. Premorbid mRS ≤1
- 6\. The degree of stenosis of extracranial arteries including internal carotid artery, vertebral artery on the lesion side ≤50%
- 7\. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion
- 8\. Signed informed consent
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurology, General Hospital of Northern Theater Command Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.